Skip to main content
. Author manuscript; available in PMC: 2019 Sep 4.
Published in final edited form as: ACS Pharmacol Transl Sci. 2019 Jul 17;2(4):247–263. doi: 10.1021/acsptsci.9b00020

Figure 1. Combination of furamidine and erythromycin displays an additive rescue of mis-splicing in DM1 patient-derived myotubes.

Figure 1.

Absolute value of the Percent Spliced-In difference between non-DM control and DM1 myotubes (|ΔPSI|) with and without treatment determined via RT-PCR. Cells were treated with either furamidine (FM) alone or erythromycin (EM) or a combination of both. (A) MBNL1 exon5, (B) MBNL2 exon5, (C) NUMA1 exon2 and (D) SYNE1 exon137 events all displayed additive mis-splicing rescue after 4 days of treatment with the combination. Treatment concentrations of 0.5 μM FM alone, 25 μM EM alone and the combination at those concentrations with the mean % rescue ± standard deviation above are denoted with arrows for each event.